深圳微芯生物科技股份有限公司关于变更注册资本、取消监事会并修订《公司章程》及其附件暨制定及修订公司部分治理制度的公告

Core Points - The company has announced changes to its registered capital, the cancellation of the supervisory board, and amendments to its Articles of Association and related governance systems [1][2][4] Group 1: Changes in Registered Capital and Governance Structure - The company completed the cancellation of 3,490,988 shares on May 31, 2024, and as of November 12, 2025, a total of 15,957 shares have been converted from convertible bonds, resulting in a new total share capital of 407,807,559 shares [1] - The supervisory board will be abolished, with its functions transferred to the audit committee of the board of directors, in accordance with the new Company Law effective from July 1, 2024 [2][4] - Amendments to the Articles of Association will include the removal of references to the supervisory board and related rules, while other non-substantive changes will also be made [3][4] Group 2: Governance System Revisions - The company will revise and establish certain governance systems to enhance operational standards and internal governance mechanisms, in line with the latest regulations from the Shanghai Stock Exchange [4][5] - Specific governance systems have been approved by the board and will be submitted for shareholder approval [5]